Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by BlueJays9293on Feb 18, 2024 10:02pm
151 Views
Post# 35887170

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Revised Communication Strategy

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Revised Communication StrategyI actually see things as slightly more dire for Vantive without PMX,  a 1% to 2% grower???  C'mon, that doesn't even keep up with inflation lol, nobody even in a great environment is after that.  A legacy company with zero innovation??

Puh-lease.

I'd rather still own AOL stock and be catching all those people that never cancelled their dial up.  LOL

They are going to have to take some chances, perceived but maybe not real, if they are going to turn that dinasaur with absolutely zero innovation into a thriver, an adapter, that is something to be proud off.

And they can't wait until post-spinoff-IPO, because by then that IPO will price at the low range of estimates at listing, and that IPO will maybe be trading down 50% shortly after it lists.  They don't want that, remember Baxter will retain 20% of Vantive stock for a year or so, they want that stock to be trading higher so they can use it to make a big dent in their residual Hill-Rom debt come 2025.

Vantive is a dead fish without us.


<< Previous
Bullboard Posts
Next >>